Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
October 18, 2024 06:47 ET
|
Novartis Pharma AG
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment...
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
October 17, 2024 05:30 ET
|
Medigene AG
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
October 16, 2024 00:30 ET
|
HUTCHMED (China) Limited
— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who...
Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain
October 15, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the...
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight
October 10, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight The need for antiemetic drugs, which help prevent or...
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
October 09, 2024 07:30 ET
|
Prelude Therapeutics, Incorporated
WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the...
Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight
October 07, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight The market for B7-H3 inhibitors is expected to grow...
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
October 07, 2024 07:00 ET
|
Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
SERD Market is Predicted to Exhibit Remarkable Growth Owing to the Usage of Faslodex in Combination, Strong Performance of ORSERDU, and Speedy Progress of Other Oral SERDs, During the Study Period (2020–2034) | DelveInsight
October 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- SERD Market is Predicted to Exhibit Remarkable Growth Owing to the Usage of Faslodex in Combination, Strong Performance of ORSERDU, and Speedy...
Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
October 01, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...